Autoimmune Disease Diagnostics Market to Generate Revenue Worth $10,012.9 Million by 2030

  • Published: July 2020

The growing incidence and prevalence of autoimmune diseases, surging geriatric population, discovery of novel biomarkers, initiatives taken by several private and government organizations to raise awareness about autoimmune diseases, and rising strategic development activities among key players are the major factors that positively impact the growth of the global autoimmune disease diagnostics market. Due to these factors, the market is expected to generate $10,012.9 million revenue in 2030, advancing at a CAGR of 8.5% during the forecast period.

The Category of Consumables and Assay Kits to Hold Larger Share in Market throughout Forecast Period

The autoimmune disease diagnostics market in terms of product is bifurcated into consumables and assay kits, and instruments. Between these two, the consumables and assay kits category is expected to lead the market in the coming years. This can be mainly ascribed to the rising prevalence of autoimmune diseases and increasing demand for tests, including enzyme-linked immunosorbent assay (ELISA), antinuclear antibody (ANA) immunofluorescence assay (IFA), and rheumatoid factor (RF) & anti-cyclic citrullinated peptide (CCP) antibody.

The autoimmune disease diagnostics market based on application is categorized into rheumatoid arthritis (RA), multiple sclerosis, systemic lupus erythematosus (SLE), Sjögren’s syndrome, scleroderma, myasthenia gravis, sarcoidosis, and others. The RA category is expected to witness fastest growth in the coming years, owing to the rising number of cases of RA, increasing awareness programs organized by various private and public organizations, and discovery of new biomarkers for the diagnosis of RA.

Geographically, the autoimmune disease diagnostics market in North America is expected to witness lucrative growth, as a result of the improved healthcare infrastructure, widespread burden of autoimmune diseases, increasing research activities, presence of established players, and surging geriatric population.

Product Launch Is Strongest Strategic Measure Taken by Players in Market

Players in the autoimmune disease diagnostics market are focusing on introducing and commercializing new products to enhance their market presence. For instance, in September 2019, F. Hoffmann-La Roche Ltd. announced that it received approval from the United States Food and Drug Administration (USFDA) for the cobas Babesia test for use on the cobas 6800/8800 systems for individual blood donation testing. It is a commercially available whole blood test to screen donations and follows May 2019 FDA-updated industry guidelines recommending screening and testing for Babesia to reduce the risk of transmitting the parasite through transfusions.

Similarly, in July 2019, the USFDA granted Abbott Laboratories the approval for Alinity s system, designed to screen new blood and plasma within a smaller space.

In addition to product launches, players in the autoimmune disease diagnostics market are engaged in collaborations and licensing to expand their consumer base. For instance, in April 2020, Nimble Therapeutics Inc. and Svar Life Science AB announced a collaboration to discover, develop, and commercialize diagnostics tests by using Nimble’s broadly applicable biomarker discovery engine and Svar’s in vitro diagnostic test development and commercialization expertise. As part of the agreement, the collaboration will initially leverage a novel panel of RA biomarkers discovered using Nimble’s comprehensive human proteome immunoprofiling. Furthermore, the collaboration is expected to play a pivotal role in combining strengths of the two organizations to potentially bring new and improved tests for patients suffering from autoimmune disorders.

Browse report overview with detailed TOC on "Autoimmune Disease Diagnostics Market Research Report: By Product (Consumables and Assay Kits, Instruments), Test Type (Routine Laboratory, Inflammatory Marker, Autoantibodies and Immunology, Human Leukocyte Antigen, Cytokine, Flow Cytometry), Application (Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Scleroderma, Myasthenia Gravis, Sarcoidosis), End User (Hospitals, Diagnosing Centers, Academic Institutes and Research Centers) - Industry Analysis and Growth Forecast to 2030" at:

Some of the major players operating in the global autoimmune disease diagnostics market include Thermo Fisher Scientific Inc., Abbott Laboratories, bioMérieux S.A., Siemens AG, Danaher Corporation, Seramun Diagnostica GmbH, F. Hoffmann-La Roche Ltd., DiaSorin S.p.A., Trinity Biotech plc, Cambridge Life Sciences Limited, , Exagen Inc., Grifols S.A., HYCOR Biomedical, ELITech Group, Inova Diagnostics, PerkinElmer Inc., Adaltis S.r.l., ORGENTEC Diagnostika GmbH, Sigma Diagnostics Inc., Bio-Rad Laboratories Inc., and A. Menarini Diagnostics S.r.l.